RDRaymond Do

Raymond Do

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Raymond Do has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Ajit Varki

    Departments of Medicine and Cellular & Molecular Medicine, University of California, San Diego, CA, 92093, USA; Center for Academic Research and Training in Anthropogeny, University of California, La Jolla, San Diego, CA, USA; Glycobiology Research and Training Center, University of California, La Jolla, San Diego, CA, USA

    2 shared publications
  • Naazneen Khan

    Department of Pharmaceutical Sciences Butler University Indianapolis Indiana USA

    2 shared publications
  • Nissi Varki

    LA JOLLA, CA)

    2 shared publications
  • Andrea Verhagen

    Departments of Medicine and Cellular & Molecular Medicine, Center for Academic Research and Training in Anthropogeny (CARTA), Glycobiology Research and Training Center (GRTC), University of California San Diego, La Jolla, California

    1 shared publication
  • Charles Wang

    Center for Genomics, School of Medicine, Loma Linda University, Loma Linda, USA

    1 shared publication
  • Gary E. Fraser

    Adventist Health Study, Research Affairs, Loma Linda University, Loma Linda, CA 92350, USA

    1 shared publication

Latest Publications

  • Open Access

    Human‐specific polymorphic pseudogenization of SIGLEC12 protects against advanced cancer progression

    by Shoib S Siddiqui, Michael Vaill, Raymond Do, Naazneen Khan, Andrea L Verhagen, Wu Zhang, Heinz‐Josef Lenz, Teresa L Johnson‐Pais, Robin J Leach, Gary Fraser, et al.

    Compared with our closest living evolutionary cousins, humans appear unusually prone to develop carcinomas (cancers arising from epithelia). The SIGLEC12 gene, which encodes the Siglec‐XII protein expressed on epithelial cells, has several uniquely human features: a fixed homozygous missense mutation inactivating its natural ligand recognition property; a polymorphic frameshift mutation eliminating full‐length protein expression in ~60%–70% of worldwide human populations; and, genomic features suggesting a negative selective sweep favoring the pseudogene state. Despite the loss of canonical sialic acid binding, Siglec‐XII still recruits Shp2 and accelerates tumor growth in a mouse model. We hypothesized that dysfunctional Siglec‐XII facilitates human carcinoma progression, correlating with known tumorigenic signatures of Shp2‐dependent cancers. Immunohistochemistry was used to detect Siglec‐XII expression on tissue microarrays. PC‐3 prostate cancer cells were transfected with Siglec‐XII and transcription of genes enriched with Siglec‐XII was determined. Genomic SIGLEC12 status was determined for four different cancer cohorts. Finally, a dot blot analysis of human urinary epithelial cells was established to determine the Siglec‐XII expressors versus non‐expressors. Forced expression in a SIGLEC12 null carcinoma cell line enriched transcription of genes associated with cancer progression. While Siglec‐XII was detected as expected in ~30%–40% of normal epithelia, ~80% of advanced carcinomas showed strong expression. Notably, >80% of late‐stage colorectal cancers had a functional SIGLEC12 allele, correlating with overall increased mortality. Thus, advanced carcinomas are much more likely to occur in individuals whose genomes have an intact SIGLEC12 gene, likely because the encoded Siglec‐XII protein recruits Shp2‐related oncogenic pathways. The finding has prognostic, diagnostic, and therapeutic implications.


  • Open Access

    Multiple Genomic Events Altering Hominin SIGLEC Biology and Innate Immunity Predated the Common Ancestor of Humans and Archaic Hominins

    by Naazneen Khan, Marc de Manuel, Stephane Peyregne, Raymond Do, Kay Prufer, Tomas Marques-Bonet, Nissi Varki, Pascal Gagneux, Ajit Varki

    Human-specific pseudogenization of the CMAH gene eliminated the mammalian sialic acid (Sia) Neu5Gc (generating an excess of its precursor Neu5Ac), thus changing ubiquitous cell surface “self-associated molecular patterns” that modulate innate immunity via engagement of CD33-related-Siglec receptors. The Alu-fusion-mediated loss-of-function of CMAH fixed ∼2–3 Ma, possibly contributing to the origins of the genus Homo. The mutation likely altered human self-associated molecular patterns, triggering multiple events, including emergence of human-adapted pathogens with strong preference for Neu5Ac recognition and/or presenting Neu5Ac-containing molecular mimics of human glycans, which can suppress immune responses via CD33-related-Siglec engagement. Human-specific alterations reported in some gene-encoding Sia-sensing proteins suggested a “hotspot” in hominin evolution. The availability of more hominid genomes including those of two extinct hominins now allows full reanalysis and evolutionary timing. Functional changes occur in 8/13 members of the human genomic cluster encoding CD33-related Siglecs, all predating the human common ancestor. Comparisons with great ape genomes indicate that these changes are unique to hominins. We found no evidence for strong selection after the Human–Neanderthal/Denisovan common ancestor, and these extinct hominin genomes include almost all major changes found in humans, indicating that these changes in hominin sialobiology predate the Neanderthal–human divergence ∼0.6 Ma. Multiple changes in this genomic cluster may also explain human-specific expression of CD33rSiglecs in unexpected locations such as amnion, placental trophoblast, pancreatic islets, ovarian fibroblasts, microglia, Natural Killer(NK) cells, and epithelia. Taken together, our data suggest that innate immune interactions with pathogens markedly altered hominin Siglec biology between 0.6 and 2 Ma, potentially affecting human evolution.